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ABSTRACT 
Introduction:  To investigate the clinical characteristics and outcomes of cancer patients with COVID-19 
infections and evaluate the effect of hepatitis B immunization status on susceptibility to COVID-19 infection 
and mortality risk. 
Materials and methods: The records of 1,515 patients who presented to the Medical Oncology clinic 
between March 2020 and December 2020 were analysed retrospectively. The demographic and clinical 
characteristics and laboratory findings of cancer patients with (case group) and without (control group) 
COVID-19 infection were compared.
Results: Of the 1,515 patients, 153 (10.1%) had been diagnosed with COVID-19, and the median age of 
cancer patients with COVID-19 infection was 53.9 (range; 18–82) years. The most common types of cancer 
were breast cancer (26.2%), gastrointestinal system cancers (22.3%), genitourinary-system cancers (16.5%) 
and lung cancer (15.5%). The presence of metastatic disease [hazard ratio (HR): 0.09, 95% CI (0.01–0.83), 
(p = 0.03)] and receipt of palliative chemotherapy in the cancer patients with COVID-19 infections [HR: 0.1, 
95% CI (0.01–0.69), (p = 0.02)] were identified as prognostic factors in multivariate analysis as univariate 
analysis did not indicate palliative treatment as a prognostic factor. When the case group and control 
groups were compared in terms of hepatitis B immunization status (p = 0.24), no statistically significant 
difference was identified between the two groups. Furthermore, hepatitis B immunization status (p = 0.37) 
were not found to be associated with COVID-19-related mortality risk.
Conclusion: Hepatitis B immunization status were not associated with the risk of COVID-19 transmission 
and mortality. The present study identified the presence of metastatic disease and palliative chemotherapy 
as negative and positive prognostic factors, respectively.
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Cancer patients have been identified as a high-
risk patient group during the COVID-19 pandemic 
[1–3]. SARS-CoV2 (severe acute respiratory syn-
drome-coronavirus-2) infection is associated with 
poorer outcomes in cancer patients than in those 
without cancer, due to associated advanced age, 
frailty, comorbidities (hypertension, diabetes, car-
diac and pulmonary diseases, etc.), malnutrition 
and treatment-related immunosuppression [3], and 
there is a further risk of COVID-19 infection due to 
the associated therapeutic applications and frequent 
hospital visits [4]. 
There is a difference in COVID-19 infection and 
mortality rates between age groups. COVID-19 infec-
tion and mortality rates are very low in the population 
between the ages of 0 and 20 years, in contrast to the 
adult population, and symptoms are milder among in-
fected children and adolescents [5]. Several hypotheses 
have been put forward to explain this finding, the first of 
which claims that the immune system of adolescents 
and children is not as mature as in adults, and so the 
immune response against the virus is not exaggerated. 
The second is that childhood vaccines, such as those 
for mumps, rubella, poliomyelitis, hepatitis A, hepatitis 
B and varicella, protect SARS-CoV-2 through cross-re-
active antibodies [6, 7]. For example, it has been shown 
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that in developing countries where the BCG vaccine 
is included in the routine vaccination program, there 
is a lower incidence and better clinical outcomes of 
COVID-19 than in developed countries without routine 
BCG vaccination [8, 9]. That said, the role of childhood 
vaccines in COVID-19 is uncertain and requires further 
research. 
Do the presence of HBV (hepatitis B virus) infection 
and HBV antibody seropositivity affect clinical outcomes 
in cancer patients with COVID-19 infections? The an-
swer to this question is not yet known. To the best of the 
authors’ knowledge, there has been no study to date 
investigating the relationship between COVID-19 and 
hepatitis B immunization status among cancer patients 
nor non-cancer patients. 
To address the abovementioned hypothesis, the 
present study investigates the clinical characteristics 
and outcomes of cancer patients with COVID-19 infec-
tions in the authors’ oncology centre and examine the 
relationship between hepatitis B immunization status 
and the risk of COVID-19 transmission and mortality. 
Materials and methods 
The files of all cancer patients who presented to the 
Dicle University Faculty of Medicine Medical Oncology 
between March and December 2020 were analysed 
retrospectively. Information on the demographic and 
clinical characteristics, treatments, and laboratory find-
ings of the patients (history of COVID-19; COVID-19 PCR 
test results; HbsAg, Anti-HBs, and Anti-Hbc IgG levels) 
were obtained from the hospital’s file registry system. 
Patients with a laboratory-confirmed SARS-CoV-2 in-
fection upon presentation to the pandemic hospital, 
i.e., patients with a positive PCR test, were accepted as 
COVID-19 cases. Those who were clinically diagnosed 
with COVID-19 but who had a negative PCR test were 
excluded from the study. Cancer patients diagnosed 
with COVID-19 (positive PCR test) were defined as 
the case group, while cancer patients not diagnosed 
with COVID-19 were defined as the control group. The 
clinical and laboratory findings and survival outcomes 
of both groups were evaluated.
Of the 1,515 patients who presented to the oncology 
clinic, 153 were diagnosed with COVID-19 infection 
during the pandemic. 1,454 of the 1,515 patients had 
hepatitis B panel tests. But the clinical data of 103 pa-
tients with COVID-19 infection were accessed from the 
archive system, among which the hepatitis B panel tests 
of 92 were available. 1362 patients, except 92 patients 
who were diagnosed with COVID-19 infection were 
defined as the control group. All statistical analyses 
were made based on these numbers of patients. The 
patients were categorized according to age, gender, 
presence of comorbidities, type of cancer diagnosis, 
disease stage (metastatic/non-metastatic), therapeutic 
applications (adjuvant/neoadjuvant therapy, palliative 
therapy and non-receipt of therapy), therapeutic agents 
(chemotherapy, immunotherapy, tyrosine kinase inhib-
itors, anti-hormonal therapies), and hepatitis B immu-
nization status (vaccinated, resolved infection, isolated 
anti-HBc Ab (+), non-immunized and HBsAg-positive), 
and the case and control groups were compared based 
on these parameters. The case groups were further 
categorized into survivors and non-survivors.
Statistics
A statistical assessment of the data was made 
using PASW Statistics (Version 18.0. Chicago: SPSS 
Inc.). Descriptive statistics were used to evaluate pa-
tient characteristics and the frequency of parameters, 
a Student-t-test was applied to normally distributed 
numerical variables; Chi-square, Fisher’s exact and 
Mann-Whitney U tests were applied for the analysis of 
non-normally distributed or non-parametric variables, 
and a logistic regression analysis was made. A multi-
variate analysis was carried out using the Cox model. 
The confidence interval of 95% and p-value of the 
significance of < 0.05 were accepted.
Results
Of the 1,515 patients who presented to the oncology 
clinic, 1,454 patients had hepatitis B panel tests. The 
study included a total of 1,454 patients, comprising 
763 (52.5%) men and 691 (47.5%) women whose data 
could be accessed. During the pandemic, 153 (10.1%) 
patients were diagnosed with COVID-19 infection. Of the 
153 patients diagnosed with COVID-19, 18 (11.7%) died. 
The general characteristics of 103 (6.8%) patients with 
fully accessible data and a diagnosis of COVID-19 in-
fection are presented in Table 1. The median age of the 
cancer patients with COVID-19 infection in the present 
study was 53.9 (range; 18–82) years. Of the patients, 
51% (n: 52) were women, and there was a history of co-
morbidities in 42.7% of the patients. The most common 
types of cancer among the COVID-19-positive patients 
were breast cancer (26.2%), gastrointestinal system 
cancers (22.3%), genitourinary system cancers (16.5%) 
and lung cancer (15.5%). There was no statistically sig-
nificant difference in mortality risk by age, gender, and 
comorbidities among patients with COVID-19 infection. 
Regarding the type of primary diagnosis, there was 
also no statistically significant difference in mortality 
risk (p = 0.76).
Metastatic disease was recorded in 60.2% (n: 62) 
of the patients, and the rate of metastatic disease was 
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Table 1. Mortality risk in patients diagnosed with Covid 19 according to disease and treatment characteristics
  N (%) Non-survivor (N%) Survivor (N%) HR (95% CI) P-value
All patients 103 18 (17.5%) 85 (82.5%)
Age (median, yrs.) 53.9 (18–82) 51 (18–80) 54 (18–82) 0.98 (0.95–1.02) 0.51
Gender 0.55 (0.19–1.56) 0.26
Male 51 (49%) 11 (61.1%) 40 (47.1%)
Female 52 (51%) 7 (38.9%) 45 (52.9%)
Comorbidities 1.45 (0.52–4.03) 0.46
Yes 44 (42.7%) 9 (50%) 35 (41.2%)
No 59 (57.3%) 9 (50%) 50 (58.8%)
Diagnosis 0.76
Brain 4 (3.9%) 1 (5.6%) 3 (3.5%) 1.66 (0.07–37.72) 0.74
GUS 17 (16.5%) 1 (5.6%) 16 (18.8%) 0.31 (0.16–5.95) 0.43
GiS 23 (22.3%) 6 (33.3%) 17 (20%) 1.76 (0.17–18.32) 0.63
Soft tissue 7 (6.8%) 1 (5.6%) 6 (7.1%) 0.83 (0.04–16.99) 0.90
Breast 27 (26.2%) 3 (16.7%) 24 (28.2%) 0.62 (0.05–7.31) 0.70
Lung/pleura 16 (15.5%) 4 (22.2%) 12 (14.1%) 1.66 (0.14–18.87) 0.68
Head and Neck 4 (3.8%) 1 (5.6%) 3 (3.5%) 1.66 (0.07–37.72) 0.74
Others 5 (4.9%) 1 (5.6%) 4 (4.7%) Reference
Stage 4.04 (1.09–15.1) 0.04
Metastatic 62 (60.2%) 15 (83.3%) 47 (55.3%)
Non-metastatic 41 (39.8%) 3 (16.7%) 38 (44.7%)
Treatment options 0.10
No treatment 15 (14.6%) 5 (27.8%) 10 (11.8%) Reference
Adjuvant/neoadjuvant 36 (35%) 3 (16.6%) 33 (38.8%) 0.17 (0.03–0.87) 0.03
Palliative 52 (50.4%) 10 (55.6%) 42 (49.4%) 0.47 (0.13–1.70) 0.25
Anti-Tumoral agents (n: 88) 0.77
Chemotherapy 54 (62.1%) 7 (58.3%) 47 (62.7%) Reference
TKi 10 (11.5%) 1 (8.3%) 9 (12%) 0.67 (0.07–6.08) 0.72
Immunotherapy 3 (3.4%) 1 (8.3%) 2 (2.7%) 3.35 (0.26–42.07) 0.34
Hormonal therapy 20 (23%) 3 (25%) 17 (22.6%) 1.18 (0.27–5.11) 0.82
* independent samples T-test.
higher in the non-survivors than in the survivors. In an 
evaluation of the association between mortality risk 
and the presence of metastatic disease, the mortality 
rate was found to be higher in patients with meta-
static disease [24.2% in metastatic patients, 7.3% in 
non-metastatic patients (HR: 4.04, 95% CI (1.09–15.1), 
(p = 0.04)]. Of the patients, 52% (n: 52) were under-
going palliative chemotherapy and 36% (n: 37) adju-
vant/neoadjuvant therapy, while 14.6% (n: 15) were 
receiving no treatment. When the sample was evaluated 
based on treatment modalities, survival was better for 
COVID-19 positive patients receiving adjuvant/neoadju-
vant therapy than for the group receiving no treatment 
[HR: 0.17, 95% CI (0.03–0.87), (p = 0.03)]. There was 
no statistically significant difference in the mortality rates 
of those receiving palliative chemotherapy and those 
undergoing no treatment [HR: 0.47, 95% CI (0.13–1.70), 
(p = 0.25)]. Of the 87 patients receiving treatment, 
62.1% (n: 54) were receiving chemotherapy, 23% (n: 
20) hormonal therapies, 11.5% (n: 10) tyrosine kinase 
inhibitors and 3.4% (n: 3) immunotherapy agents. When 
the treatments of the patients were compared, no sta-
tistically significant difference was found in the mortality 
rates associated with the different therapeutic agents 
(p = 0.77). 
When the total 1,454 patients were evaluated in 
terms of hepatitis B immunization, data was available 
for 92 patients with a COVID-19 diagnosis and 1,362 pa-
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Table 3. Multivariate analysis for mortality risk in patients with COVID-19
        Multivariate analysis
  HR (95% CI) P-value
Age 0.96 (0.91–1.01) 0.20
Gender (male/female) 0.43 (0.11–1.71) 0.23
Comorbidities (no/yes) 2.00 (0.41–9.73) 0.39
Stage (metastatic/ non-metastatic) 11.16 (1.19–104.6) 0.03
Treatment options 0.06
No treatment reference
Adjuvant/neoadjuvant 0.43 (0.05–3.79) 0.45
Palliative 0.10 (0.01–0.69) 0.02
Hepatitis B immunization (no/yes) 0.43 (0.11–1.62) 0.21
tients in the control group. The detailed clinical and 
laboratory findings of the patients related to hepatitis B 
are presented in Table 2. The seroprevalence of hepa-
titis B (HbsAg +) was 6% (87/1454) among the study 
patients. In the case group, 4.3% (n: 4) of patients had 
HbsAg positivity, 60.9% (n: 56) had anti-Hbs positivity 
and 52.2% (n: 24) had anti-HBc IgG positivity. In the 
control group, 6.1% (n: 83) of the patients had HbsAg 
positivity, 61.5% (n: 838) had anti-Hbs positivity and 
49.6% (n: 421) had anti-Hbc IgG positivity. The mean 
anti-Hbs level was 10 IU/L in the case group compared 
with 18.2 IU/L in the control group (p = 0.66). When 
the immunization status of the patients was analysed, 
44.6% (n: 41) of the patients were found to be vacci-
nated, 15.2% (n: 14) had resolved infection, 8.7% (n: 
8) had isolated anti-Hbc IgG antibody positivity, 27.2% 
(n: 25) were non-immunized and 4.3% (n: 4) were HbsAg 
positive in the case group. In the control group, in turn, 
45.7% (n: 623) were vaccinated, 14.1% (n: 192) had 
resolved infection, 14.9% (n: 203) had isolated anti-Hbc 
IgG antibody positivity, 19.2% (n: 261) were non-immu-
nized, and 6.1% (n: 83) were HbsAg positive. When the 
case and control groups were compared according to 
these five categories, there was no statistically signif-
icant difference in the risk of COVID-19 transmission 
(p = 0.22) or the risk of mortality (p = 0.22) between 
the groups. When the patients’ anti-Hbs antibody 
levels (< 2 IU/L, 2–9 IU/L, 10–99 IU/L, 100–999 IU/L 
and > 1000 IU/L) were categorized, no statistically sig-
nificant difference was found between the two groups 
in the risk of COVID-19 transmission (p = 0.43) and the 
risk of mortality (p = 0.53) based on antibody levels. 
Age, gender, presence of comorbidities, stage of 
the disease, treatment options, hepatitis B immunization 
status were examined with univariate and multivariate 
analyses. The results of the analyses are presented in 
Table 3. The multivariate analysis identified palliative 
chemotherapy [HR: 0.1, 95% CI (0.01–0.69), (p = 0.02)] 
and stage [HR: 0.09, 95% CI (0.01–0.83), (p = 0.03)] as 
independent prognostic factors for mortality risk in pa-
tients with COVID-19 infection as univariate analysis did 
not indicate palliative treatment as a prognostic factor.
Discussion
Among the different patient groups, cancer patients 
are at one of the greatest risks from the COVID-19 pan-
demic [1–3]. The present study investigates the effect 
of the characteristic and clinical outcomes of cancer 
patients who presented to the authors’ clinic during the 
COVID-19 pandemic related to COVID-19 transmission 
risk and mortality, intending to identify the associated 
risk factors. 
Among the 1,515 patients who presented to the clin-
ic during the pandemic, 10.1% (n: 153) were diagnosed 
with COVID-19, which is a rate considerably higher than 
reported in COVID-19 incidence studies conducted 
with cancer patients (10.1% vs. 0.79–1.3%) [10, 11]. 
This may be attributed to the fact that the reported 
studies were carried out during the early stages of the 
pandemic, and that cases increased afterwards, and 
that a COVID-19 test was administered routinely to the 
patients before treatment following the recommended 
guidelines later in the pandemic, leading to the detec-
tion also of asymptomatic cases.
The Southeastern Anatolia Region of Turkey, where 
the oncology centre is located, is an endemic area 
for hepatitis B infection (7%, with a high prevalence 
of HBsAg) [12], and so all patients referring to the 
oncology centre are routinely checked for hepatitis B 
serology with Elisa before treatment planning. Che-
motherapy-induced immunosuppression may cause 
HBV reactivation in active or inactive HBV carriers, and 
HBV reactivation during anti-tumour therapy can lead 
to life-threatening clinical manifestations (fulminant 
Zeynep Oruç et al., COVID-19 and Hepatitis B
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hepatitis, hepatic failure, and mortality) in addition to 
discontinuation of anti-tumour therapies [13]. Guide-
lines recommend HBV screening for treatments with 
severe immunosuppressive activity or patients at high 
risk of HBV infection, and prophylactic antiviral therapy 
in cancer patients at high risk of HBV reactivation [12, 
13]. In the present study, 34.7% of cases had encoun-
tered hepatitis B at some point in their lives, and 6% 
had HbsAg positivity. The seroprevalence of hepatitis 
B among patients was consistent with the prevalence 
of hepatitis B in the study region (6% vs. 7%), and there 
was no significant difference in HbsAg positivity between 
the patients with COVID-19 and the control group [4.3% 
vs. 6.1% (p = 0.56)].
Whether or not hepatitis B seropositivity and im-
munization status affect the course and outcomes of 
COVID-19 infection are yet to be confirmed. Chronic 
HBV infection may affect the likelihood of develop-
ing clinically important infectious manifestation with 
COVID-19 [13–15]. A review article suggested that 
chronic HBV infection may contribute to a decrease in 
virus-specific T-cell activity, and indirectly to the inten-
sity of the cytokine storm [16]. It is also hypothesized 
that immunization with hepatitis A, hepatitis B and 
BCG vaccines can provide a protective effect against 
COVID-19 through immune maturation [6]. That said, 
in an animal study investigating whether childhood 
vaccines, including hepatitis B and BCG, produced 
cross-reactive neutralizing antibodies against SARS-
CoV-2, none were found to produce antibodies against 
SARS-CoV-2 after vaccination [17]. In the present 
study, when the immunization profiles (vaccinated, 
resolved infection, isolated anti-HBc Ab (+), non-im-
munized and HBsAg-positive) developed against 
hepatitis B were compared between the case and 
control groups, no significant difference was noted in 
the risk of COVID-19 transmission between the groups 
(p = 0.22), and no significant difference was noted 
either in mortality risk between the different immuniza-
tion profiles of COVID-19-positive patients (p = 0.37). It 
was further observed that anti-Hbs serum levels had no 
effect on COVID-19 transmission (p = 0.44) or mortality 
(p = 0.60).
COVID-19 infections can lead to impaired liver 
function and severe liver injury [18]. A meta-anal-
ysis of studies evaluating the hepatic findings of 
COVID-19 reported an HBV prevalence of 0.9% [19]. 
The prevalence of HBV infection was found to be 
6.1% and 4.3% in the study control group patients 
with a cancer diagnosis and cancer patients with 
COVID-19, respectively. Although these rates seem 
higher than those reported in the literature, they 
were close to the prevalence (7%) of the endemic 
region in the general population. In a previous study 
evaluating the clinical characteristics of patients with 
hepatitis B and COVID-19 coinfection, 20 (6.1%) of 
326 COVID-19 positive patients had concurrent HBV 
infection. The study found no significant difference in 
discharge rates, length of hospital stays, exacerbation 
of liver injury, and mortality between the patients with 
and without hepatitis B infection [20].
Among cancer patients, those with thoracic malig-
nancies such as lung cancer are considered at high 
risk of COVID-19 mortality due to associated age, co-
morbidities, history of smoking and existing pulmonary 
damage, in addition to the treatments administered 
for the disease [21]. In the present study, lung cancer 
was the fourth most common form of cancer after 
breast, gastrointestinal system (GIS) and genitourinary 
system (GUS) cancers, among the study patients with 
COVID-19 infection. However, lung cancers did not dif-
fer from the other cancer types in terms of COVID-19-re-
lated mortality risk (p = 0.68). 
In the present study, multivariate analysis showed 
that the presence of metastatic disease and the receipt 
of palliative chemotherapy were statistically different 
between the survivors and non-survivors among the 
cancer patients with COVID-19 infection as univariate 
analysis did not indicate palliative treatment as a prog-
nostic factor. Survival among the COVID-19 positive 
patients receiving palliative therapy was better than in 
those receiving no treatment [HR: 0.1, 95% CI (0.01–
0.69), (p = 0.02)]. Most patients in the group receiving 
no treatment were in remission. Although this would 
appear to be contradictory, it actually recalls the idea 
that chemotherapy can suppress possible excessive im-
mune reactions (cytokine storm) due to COVID-19 and 
can provide a survival benefit to the patients. In this re-
gard, a previous study comparing the immune response 
to SARS-CoV-2 in cancer patients undergoing active 
antitumor therapy with the immune response in healthy 
individuals reported differences in immune cell profiles, 
indicating different inflammatory responses in the two 
groups. The study suggested that cancer treatments 
such as chemotherapy, biological agents and immu-
notherapies may affect the body’s immune response 
against COVID-19, leading to a milder manifestation of 
the infection in cancer patients with COVID-19 infection 
[22]. Also, fewer myelosuppressive therapeutic agents 
were preferred for palliative chemotherapies, and dose 
reductions and delays were applied more frequently 
during the pandemic, following the recommended 
guidelines [23]. In contrast, granulocyte colony-stimu-
lating factor (GCSF) support was more often preferred 
for the minimization of the risk of myelosuppression. 
Likely, these adaptive practices may also influence the 
study findings.
The present study was unable to identify any statis-
tical differences in the treatments of the survivors and 
non-survivors diagnosed with COVID-19. The potential 
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interaction between oncological therapeutic agents and 
COVID-19 infection is not fully known [24], although 
the TERAVOLT study, which investigated the risk fac-
tors associated with mortality in patients with thoracic 
malignancies and COVID-19 infections and presented 
at ASCO 2020’s meeting (American society of clinical 
oncology 2020), reported the treatment of cancer pa-
tients with chemotherapy to be a risk factor for mortality 
associated with COVID-19 infection, while treatment with 
tyrosine kinase inhibitors and immunotherapy was not 
a risk factor. The same study further reported advanced 
age (> 65 years), comorbidities, performance status > 1, 
and receiving steroid or anticoagulant therapy to be risk 
factors associated with mortality [21]. In a comparison of 
the patients in the present study in terms of the applied 
anti-tumour therapies (chemotherapy, immunotherapy, 
tyrosine kinase inhibitor and hormonal therapies), it 
was observed that types of anti-tumour therapy did not 
affect mortality in patients with COVID-19 infection. In 
a study conducted in the early stages of the pandemic 
that evaluated cancer patients with COVID-19 infection, 
the receipt of chemotherapy within four weeks of the 
emergence of COVID-19 infection symptoms and male 
gender were reported to be poor prognostic factors. In 
addition, hepatitis B virus infection was detected in 6% 
of the 205 patients in the study, although the same 
study observed that the presence of hepatitis B virus 
infection was not among the risk factors for mortality 
[25]. A study by Lee et al., in turn, reported the receipt 
of chemotherapy within the last four weeks to have no 
significant effect on COVID-19 mortality, while advanced 
age and the presence of cardiovascular comorbidities 
were high-risk factors [26]. Cancer patients undergo-
ing active treatment have been referred to as high-risk 
patients since the beginning of the pandemic. After 
viewing the findings of different studies, it is expected 
that the potential roles of cancer and cancer treatments 
during COVID-19 will be clarified through further studies.
The limitations of this study include its single-centre 
and retrospective design, the heterogeneous patient 
population in terms of diagnosis, stage and treatments, 
and the lack of information about COVID-19 treatments 
(such as steroids, etc.) that might have an impact on 
mortality risk. Moreover, the fact that the study was 
carried out in one particular region in the country, and 
that the patient group had other diseases, may have 
influenced the study findings. Finally, some of the 
control group patients may contract COVID-19 in the 
future, which is another study limitation.
Conclusions
In conclusion, this study is the first to evaluate 
the relationship between COVID-19 and hepatitis B 
immunization in cancer patients. The present study 
identified the presence of metastatic disease and 
the receipt of palliative chemotherapy as negative 
and positive prognostic factors, respectively, but no 
statistically significant relationship between the risk of 
COVID-19 transmission and mortality, and hepatitis 
B immunization status. Factors other than hepatitis B 
immunization status are likely to be more effective in 
the risk of COVID-19 transmission and mortality among 
cancer patients.
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